Search

Your search keyword '"Zuleger, Cindy L"' showing total 31 results
Start Over Author "Zuleger, Cindy L"
31 results on '"Zuleger, Cindy L"'

7. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Author

Albertini, Mark R., Yang, Richard K., Ranheim, Erik A., Hank, Jacquelyn A., Zuleger, Cindy L., Weber, Sharon, Neuman, Heather, Hartig, Greg, Weigel, Tracey, Mahvi, David, Henry, Mary Beth, Quale, Renae, McFarland, Thomas, Gan, Jacek, Carmichael, Lakeesha, Kim, KyungMann, Loibner, Hans, Gillies, Stephen D., and Sondel, Paul M.

Published
2018
Full Text
View/download PDF

10. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting

Author

Magee, Kara, primary, Marsh, Ian R., additional, Turek, Michelle M., additional, Grudzinski, Joseph, additional, Aluicio-Sarduy, Eduardo, additional, Engle, Jonathan W., additional, Kurzman, Ilene D., additional, Zuleger, Cindy L., additional, Oseid, Elizabeth A., additional, Jaskowiak, Christine, additional, Albertini, Mark R., additional, Esbona, Karla, additional, Bednarz, Bryan, additional, Sondel, Paul M., additional, Weichert, Jamey P., additional, Morris, Zachary S., additional, Hernandez, Reinier, additional, and Vail, David M., additional

Published
2021
Full Text
View/download PDF

11. Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

Author

Albertini, Mark R., primary, Morris, Zachary Scott, additional, Hank, Jacquelyn A, additional, Ranheim, Erik, additional, Zuleger, Cindy L, additional, McDowell, Kimberly, additional, Quale, Renae M, additional, Monson, Molly, additional, Clements, Erin, additional, Koehn, Tamara, additional, Neuman, Heather B., additional, Weber, Sharon M., additional, Racz, Jennifer, additional, Henry, Mary Beth, additional, Reinstad, Emily, additional, Kim, KyungMann, additional, Gillies, Stephen D., additional, and Sondel, Paul M., additional

Published
2021
Full Text
View/download PDF

19. Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma

Author

Zuleger, Cindy L., primary, Sondel, Paul M., additional, Hank, Jacquelyn A., additional, Ranheim, Erik A., additional, McFarland, Thomas A., additional, Collins, Jennifer, additional, Clements, Erin, additional, Whalen, Giles, additional, Galili, Uri, additional, and Albertini, Mark R., additional

Published
2014
Full Text
View/download PDF

20. Clonal Expansions of 6-Thioguanine Resistant T Lymphocytes in the Blood and Tumor of Melanoma Patients1

Author

Albertini, Mark R., Macklin, Michael D., Zuleger, Cindy L., Newton, Michael A., Judice, Stephen A., and Albertini, Richard J.

Subjects
Hypoxanthine Phosphoribosyltransferase, T-Lymphocytes, Drug Resistance, Receptors, Antigen, T-Cell, Lymphocyte Activation, Article, Clone Cells, Lymphocytes, Tumor-Infiltrating, Neoplasms, Mutation, Humans, Thioguanine, Melanoma, Cell Proliferation
Abstract

The identification of specific lymphocyte populations that mediate tumor immune responses is required for elucidating the mechanisms underlying these responses and facilitating therapeutic interventions in humans with cancer. To this end, mutant hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficient (HPRT-) T-cells were used as probes to detect T-cell clonal amplifications and trafficking in vivo in patients with advanced melanoma. Mutant T-cells from peripheral blood were obtained as clonal isolates or in mass cultures in the presence of 6-thioguanine (TG) selection and from tumor-bearing lymph nodes (LNs) or metastatic melanoma tissues by TG-selected mass cultures. Nonmutant (wild-type) cells were obtained from all sites by analogous means, but without TG selection. cDNA sequences of the T-cell receptor (TCR) beta chains (TCR-beta), determined directly (clonal isolates) or following insertion into plasmids (mass cultures), were used as unambiguous biomarkers of in vivo clonality of mature T-cell clones. Clonal amplifications, identified as repetitive TCR-beta V-region, complementarity determining region 3 (CDR3), and J-region gene sequences, were demonstrated at all sites studied, that is, peripheral blood, LNs, and metastatic tumors. Amplifications were significantly enriched among the mutant compared with the wild-type T-cell fractions. Importantly, T-cell trafficking was manifested by identical TCR-beta cDNA sequences, including the hypervariable CDR3 motifs, being found in both blood and tissues in individual patients. The findings described herein indicate that the mutant T-cell fractions from melanoma patients are enriched for proliferating T-cells that infiltrate the tumor, making them candidates for investigations of potentially protective immunological responses.

Published
2008

21. MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair

Author

Bhatia, Neehar, primary, Xiao, Tony Z., additional, Rosenthal, Kimberly A., additional, Siddiqui, Imtiaz A., additional, Thiyagarajan, Saravanan, additional, Smart, Brendan, additional, Meng, Qiao, additional, Zuleger, Cindy L., additional, Mukhtar, Hasan, additional, Kenney, Shannon C., additional, Albertini, Mark R., additional, and Jack Longley, B., additional

Published
2013
Full Text
View/download PDF

23. NK cells propagate T cell immunity following in situtumor vaccination

Author

Jin, Won Jong, Jagodinsky, Justin C., Vera, Jessica M., Clark, Paul A., Zuleger, Cindy L., Erbe, Amy K., Ong, Irene M., Le, Trang, Tetreault, Kaitlin, Berg, Tracy, Rakhmilevich, Alexander L., Kim, KyungMann, Newton, Michael A., Albertini, Mark R., Sondel, Paul M., and Morris, Zachary S.

Abstract

We report an in situvaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2 (IL-2; 3xTx). In a phase I clinical trial, administration of 3xTx (with an immunocytokine fusion of tumor-specific antibody and IL-2, hu14.18-IL2) to subjects with metastatic melanoma increases peripheral CD8+T cell effector polyfunctionality. This suggests the potential for 3xTx to promote antitumor immunity against metastatic tumors. In poorly immunogenic syngeneic murine melanoma or head and neck carcinoma models, 3xTx stimulates CD8+T cell-mediated antitumor responses at targeted and non-targeted tumors. During 3xTx treatment, natural killer (NK) cells promote CTLA4+regulatory T cell (Treg) apoptosis in non-targeted tumors. This is dependent on NK cell expression of CD86, which is upregulated downstream of KLRK1. NK cell depletion increases Treginfiltration, diminishing CD8+T cell-dependent antitumor response. These findings demonstrate that NK cells sustain and propagate CD8+T cell immunity following 3xTx.

Published
2023
Full Text
View/download PDF

27. A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients

Author

Cassaday, Ryan D., primary, Sondel, Paul M., additional, King, David M., additional, Macklin, Michael D., additional, Gan, Jacek, additional, Warner, Tom F., additional, Zuleger, Cindy L., additional, Bridges, Alan J., additional, Schalch, Heidi G., additional, Kim, Kyung Mann, additional, Hank, Jacquelyn A., additional, Mahvi, David M., additional, and Albertini, Mark R., additional

Published
2007
Full Text
View/download PDF

29. Peptide induces CD4+CD25+ and IL-10+ T cells and protection in airway allergy models

Author

Zuleger, Cindy L., Gao, Xiaoyan, Burger, Melissa S., Chu, Qili, Payne, Lendon G., and Chen, Dexiang

Subjects
*EOSINOPHIL disorders, *VACCINATION, *INTRAPERITONEAL injections, *T cells
Abstract

Abstract: The purpose of this study was to evaluate whether a single peptide containing a major T cell epitope might induce peripheral tolerance in a complex allergen model. C57BL/6 mice were sensitized by intraperitoneal injection of house dust mite extract (HDM), and exposed to antigen via trachea instillation. Der p 1 peptide was administered by i.v. before or after sensitization. Lung lavage fluids were analyzed for cellular infiltration. Respiratory exposure of sensitized mice to antigen results in airway inflammation and eosinophilia. Intravenous administration of a single peptide protected sensitized mice from these changes. Further, the emergence of antigen-specific CD25+CD4+ and IL-10 secreting cell populations in DO11.10 mice was demonstrated after peptide administration. Thus, intravenous delivery of a single peptide epitope is capable of inducing peripheral tolerance and protection in a complex allergy model, possibly through regulatory T cells and bystander suppression. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

30. SURROGATE SELECTION OVERSAMPLES EXPANDED T CELL CLONOTYPES.

Author

Yu P, Lian Y, Zuleger CL, Albertini RJ, Albertini MR, and Newton MA

Abstract

Inference from immunological data on cells in the adaptive immune system may benefit from modeling specifications that describe variation in the sizes of various clonal sub-populations. We develop one such specification in order to quantify the effects of surrogate selection assays, which we confirm may lead to an enrichment for amplified, potentially disease-relevant T cell clones. Our specification couples within-clonotype birth-death processes with an exchangeable model across clonotypes. Beyond enrichment questions about the surrogate selection design, our framework enables a study of sampling properties of elementary sample diversity statistics; it also points to new statistics that may usefully measure the burden of somatic genomic alterations associated with clonal expansion. We examine statistical properties of immunological samples governed by the coupled model specification, and we illustrate calculations in surrogate selection studies of melanoma and in single-cell genomic studies of T cell repertoires.

Published
2023
Full Text
View/download PDF

31. Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment.

Author

Maa YF, Ameri M, Shu C, Zuleger CL, Che J, Osorio JE, Payne LG, and Chen D

Subjects
Administration, Cutaneous, Animals, Disaccharides chemistry, Drug Stability, Excipients chemistry, Female, Guinea Pigs, Hepatitis B Surface Antigens genetics, Hepatitis B Vaccines administration & dosage, Hepatitis B Vaccines immunology, Immunization methods, Immunoenzyme Techniques methods, Injections, Intramuscular, Lysine chemistry, Mice, Mice, Inbred BALB C, Microscopy, Electron, Scanning, Microspheres, Nanoparticles chemistry, Particle Size, Poloxamer chemistry, Powders, Sepharose chemistry, Hepatitis B Surface Antigens immunology, Hepatitis B Vaccines chemistry, Technology, Pharmaceutical methods
Abstract

The purpose of this study was to develop a hepatitis-B surface antigen (HBsAg) dry powder vaccine formulation suitable for epidermal powder immunization (EPI) via an efficient, scalable powder-formation process. Several HBsAg dry powder formulations were prepared using four different powder-formation methods: freeze-drying/compress/grind/sieve (FD/C/G/S), spray-drying (SD), agarose beads, and spray freeze-drying (SFD). Powder properties and physical stability were determined using particle size analysis, tap density measurement, scanning electron microscopy, optical microscopy, and moisture content analysis. Physical, chemical and biochemical stability of HBsAg was determined by dynamic light scattering, an enzyme immune assay, and immunogenicity in a mouse or hairless guinea pig model. Out of the four powder-formation methods evaluated SFD outperformed other methods in the following considerations: good process efficiency, flexible scalability, and desirable particle characteristics for skin penetration. The stress posed by SFD appeared to be mild as HBsAg in the dry form retained its potency and immunogenicity. Notably, the mechanism of fast freezing by SFD actually promoted the preservation of HBsAg nanoparticle size, in good correlation with long-term biochemical stability. Among several formulations screened, the formulation containing 10 microg HBsAg in 1-mg powder with a tertiary mixture of trehalose, mannitol, and dextran, exhibited excellent overall stability performance. In conclusion, HBsAg dry powder formulations suitable for EPI were successfully prepared using SFD. Further, a systematic formulation development strategy allowed the development and optimization of an HBsAg dry powder formulation, demonstrating excellent long-term physical, biochemical, and immunological stability.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results